| Literature DB >> 31266785 |
Marlies J W Peeters1, Donata Dulkeviciute2, Arianna Draghi2, Cathrin Ritter3, Anne Rahbech2, Signe K Skadborg2, Tina Seremet2, Ana Micaela Carnaz Simões2, Evelina Martinenaite2, Hólmfridur R Halldórsdóttir2, Mads Hald Andersen2, Gitte Holmen Olofsson2, Inge Marie Svane2,4, Lene Juel Rasmussen5, Özcan Met2,4,6, Jürgen C Becker3, Marco Donia2,4, Claus Desler5, Per Thor Straten1,6.
Abstract
The TAM family of receptor tyrosine kinases (TYRO3, AXL, and MERTK) is known to be expressed on antigen-presenting cells and function as oncogenic drivers and as inhibitors of inflammatory responses. Both human and mouse CD8+ T cells are thought to be negative for TAM receptor expression. In this study, we show that T-cell receptor (TCR)-activated human primary CD8+ T cells expressed MERTK and the ligand PROS1 from day 2 postactivation. PROS1-mediated MERTK signaling served as a late costimulatory signal, increasing proliferation and secretion of effector and memory-associated cytokines. Knockdown and inhibition studies confirmed that this costimulatory effect was mediated through MERTK. Transcriptomic and metabolic analyses of PROS1-blocked CD8+ T cells demonstrated a role of the PROS1-MERTK axis in differentiation of memory CD8+ T cells. Finally, using tumor-infiltrating lymphocytes (TIL) from melanoma patients, we show that MERTK signaling on T cells improved TIL expansion and TIL-mediated autologous cancer cell killing. We conclude that MERTK serves as a late costimulatory signal for CD8+ T cells. Identification of this costimulatory function of MERTK on human CD8+ T cells suggests caution in the development of MERTK inhibitors for hematologic or solid cancer treatment. ©2019 American Association for Cancer Research.Entities:
Year: 2019 PMID: 31266785 DOI: 10.1158/2326-6066.CIR-18-0841
Source DB: PubMed Journal: Cancer Immunol Res ISSN: 2326-6066 Impact factor: 11.151